http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 08 Sep 2026 16:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Celldex+to+Present+at+Upcoming+Investor+Conference/27036481.html <p align="left"> HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.</p> <p align="left">The webcast of the presentation will be available on the “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=u0ewxENfwoyiwWAWsi2UfxWLN571ucfw2n4mVGFa54oZ6Ph9F3QQ6n73ZlEXAk5J8Mj6Cz8xC0_wYIprGiS5RWVDxKqCVMW-wE80PozI9Y3hq0wUSunzkATeS9KfHGW6" rel="nofollow" target="_blank">Events and Presentations</a>” page of the “Investors” section of the Celldex Website. Replays will be available for 90 days following the event.</p> <p align="left"><strong>About Celldex</strong><br/>Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based http://www.streetinsider.com/Press+Releases/Celldex+to+Present+at+Upcoming+Investor+Conference/27036481.html Tue, 08 Sep 2026 16:01:00 -0400 CLDX http://www.streetinsider.com/Globe+Newswire/Celldex+to+Present+at+Upcoming+Investor+Conference/27036481.html <p align="left"> HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.</p> <p align="left">The webcast of the presentation will be available on the “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=u0ewxENfwoyiwWAWsi2UfxWLN571ucfw2n4mVGFa54oZ6Ph9F3QQ6n73ZlEXAk5J8Mj6Cz8xC0_wYIprGiS5RWVDxKqCVMW-wE80PozI9Y3hq0wUSunzkATeS9KfHGW6" rel="nofollow" target="_blank">Events and Presentations</a>” page of the “Investors” section of the Celldex Website. Replays will be available for 90 days following the event.</p> <p align="left"><strong>About Celldex</strong><br/>Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based http://www.streetinsider.com/Globe+Newswire/Celldex+to+Present+at+Upcoming+Investor+Conference/27036481.html Tue, 08 Sep 2026 16:01:00 -0400 CLDX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26927634.html si-local-file:///var/storage/secattach/20260814/26927634.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26927634.html Fri, 14 Aug 2026 12:09:00 -0400 CLDX O.31464559 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26927634.html si-local-file:///var/storage/secattach/20260814/26927634.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26927634.html Fri, 14 Aug 2026 12:09:00 -0400 CLDX O.31464559 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+PRICE+T+ROWE+ASSOCIATES+INC+MD/26926600.html si-local-file:///var/storage/secattach/20260814/26926600.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+PRICE+T+ROWE+ASSOCIATES+INC+MD/26926600.html Fri, 14 Aug 2026 10:39:00 -0400 CLDX O.31464559 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+PRICE+T+ROWE+ASSOCIATES+INC+MD/26926600.html si-local-file:///var/storage/secattach/20260814/26926600.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Celldex+Therapeutics%2C++++++++++++++++++Filed+by%3A+PRICE+T+ROWE+ASSOCIATES+INC+MD/26926600.html Fri, 14 Aug 2026 10:39:00 -0400 CLDX O.31464559 http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Raised+to+%2453+at+Barclays/26886488.html Barclays analyst Etzer Darout raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $53.00 (from $48.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Raised+to+%2453+at+Barclays/26886488.html Fri, 07 Aug 2026 04:53:38 -0400 CLDX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Celldex+Therapeutics%2C+++++For%3A+Jun+30/26883737.html si-local-file:///var/storage/secattach/20260806/26883737.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Celldex+Therapeutics%2C+++++For%3A+Jun+30/26883737.html Thu, 06 Aug 2026 16:07:00 -0400 CLDX O.31464559 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Celldex+Therapeutics%2C+++++For%3A+Jun+30/26883737.html si-local-file:///var/storage/secattach/20260806/26883737.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Celldex+Therapeutics%2C+++++For%3A+Jun+30/26883737.html Thu, 06 Aug 2026 16:07:00 -0400 CLDX O.31464559 http://www.streetinsider.com/Earnings/Celldex+%28CLDX%29+Tops+Q2+EPS+by+12c/26883456.html <p>Celldex (NASDAQ: CLDX) reported Q2 EPS of ($0.94), $0.12 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $22 thousand versus the consensus estimate of $802.64 thousand.</p><p>For earnings history and earnings-related data on Celldex (CLDX) <a href="http://www.streetinsider.com/ec_earnings.php?q=CLDX">click here</a>.</p> http://www.streetinsider.com/Earnings/Celldex+%28CLDX%29+Tops+Q2+EPS+by+12c/26883456.html Thu, 06 Aug 2026 16:05:09 -0400 CLDX http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Press+Releases/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html <ul type="disc"><li><em>Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027</em></li><li><em>Phase 3 barzolvolimab </em><em>cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) </em><em>actively enrolling; Phase 2 topline data in AD expected in late 2026 </em></li><li><em>Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and CDX-622 was well tolerated; Phase 1 CDX-622 proof of mechanism study in asthma ongoing</em><br/></li></ul> <p>HAMPTON, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the second quarter http://www.streetinsider.com/Globe+Newswire/Celldex+Reports+Second+Quarter+Financial+Results+and+Provides+Corporate+Update/26883294.html Thu, 06 Aug 2026 16:01:00 -0400 A.10662136 A.50201579 CLDX O.12524441 O.31464559 O.36397598 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celldex+Therapeutics%2C+++++For%3A+Aug+06/26883313.html si-local-file:///var/storage/secattach/20260806/26883313.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celldex+Therapeutics%2C+++++For%3A+Aug+06/26883313.html Thu, 06 Aug 2026 16:01:00 -0400 CLDX O.31464559 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celldex+Therapeutics%2C+++++For%3A+Aug+06/26883313.html si-local-file:///var/storage/secattach/20260806/26883313.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Celldex+Therapeutics%2C+++++For%3A+Aug+06/26883313.html Thu, 06 Aug 2026 16:01:00 -0400 CLDX O.31464559 http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Raised+to+%2472+at+Wells+Fargo/26831051.html Wells Fargo analyst Derek Archila raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $72.00 (from $48.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Celldex+Therapeutics+%28CLDX%29+PT+Raised+to+%2472+at+Wells+Fargo/26831051.html Wed, 29 Jul 2026 08:13:26 -0400 CLDX